173 related articles for article (PubMed ID: 12605277)
21. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading.
Dimitrakopoulou-Strauss A; Strauss LG; Schwarzbach M; Burger C; Heichel T; Willeke F; Mechtersheimer G; Lehnert T
J Nucl Med; 2001 May; 42(5):713-20. PubMed ID: 11337565
[TBL] [Abstract][Full Text] [Related]
22. Can FDG PET be used to successfully direct preoperative biopsy of soft tissue tumours?
Hain SF; O'Doherty MJ; Bingham J; Chinyama C; Smith MA
Nucl Med Commun; 2003 Nov; 24(11):1139-43. PubMed ID: 14569167
[TBL] [Abstract][Full Text] [Related]
23. Positron emission tomography (18)F-fluorodeoxyglucose uptake and prognosis in patients with bone and soft tissue sarcoma: A meta-analysis.
Li YJ; Dai YL; Cheng YS; Zhang WB; Tu CQ
Eur J Surg Oncol; 2016 Aug; 42(8):1103-14. PubMed ID: 27189833
[TBL] [Abstract][Full Text] [Related]
24. [18F-FDG-PET-CT in soft tissue sarcomas: when to image?].
Rodríguez-Alfonso B; Mucientes Rasilla J; Mitjavila Casanovas M; Cardona Arboniés J; Cubedo R
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):43-9. PubMed ID: 24094372
[No Abstract] [Full Text] [Related]
25. F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors.
Peterson JJ
Semin Musculoskelet Radiol; 2007 Sep; 11(3):246-60. PubMed ID: 18260035
[TBL] [Abstract][Full Text] [Related]
26. 18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients.
Walter F; Federman N; Apichairuk W; Nelson S; Phelps ME; Allen-Auerbach M; Walter MA; Czernin J
Pediatr Hematol Oncol; 2011 Oct; 28(7):579-87. PubMed ID: 21936620
[TBL] [Abstract][Full Text] [Related]
27. Spindle Cell Sarcoma of the Iliac Vein on 18 F-FDG PET/CT.
Bek CS; Kim HW; Won KS; Song BI
Clin Nucl Med; 2017 Apr; 42(4):293-294. PubMed ID: 28134693
[TBL] [Abstract][Full Text] [Related]
28. FDG-PET for evaluating musculoskeletal tumors: a review.
Aoki J; Endo K; Watanabe H; Shinozaki T; Yanagawa T; Ahmed AR; Takagishi K
J Orthop Sci; 2003; 8(3):435-41. PubMed ID: 12768492
[TBL] [Abstract][Full Text] [Related]
29. Functional image in soft tissue sarcomas: An update of the indications of
Rodríguez-Alfonso B; Simó-Perdigó M; Orcajo Rincón J
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):233-243. PubMed ID: 32616457
[TBL] [Abstract][Full Text] [Related]
30. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET.
Jones DN; McCowage GB; Sostman HD; Brizel DM; Layfield L; Charles HC; Dewhirst MW; Prescott DM; Friedman HS; Harrelson JM; Scully SP; Coleman RE
J Nucl Med; 1996 Sep; 37(9):1438-44. PubMed ID: 8790188
[TBL] [Abstract][Full Text] [Related]
31. Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study.
Dimitrakopoulou-Strauss A; Strauss LG; Egerer G; Vasamiliette J; Mechtersheimer G; Schmitt T; Lehner B; Haberkorn U; Stroebel P; Kasper B
J Nucl Med; 2010 Apr; 51(4):551-8. PubMed ID: 20351350
[TBL] [Abstract][Full Text] [Related]
32. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma.
van Ginkel RJ; Hoekstra HJ; Pruim J; Nieweg OE; Molenaar WM; Paans AM; Willemsen AT; Vaalburg W; Koops HS
J Nucl Med; 1996 Jun; 37(6):984-90. PubMed ID: 8683328
[TBL] [Abstract][Full Text] [Related]
33. Clinical implications of determination of safe surgical margins by using a combination of CT and 18FDG-positron emission tomography in soft tissue sarcoma.
Yokouchi M; Terahara M; Nagano S; Arishima Y; Zemmyo M; Yoshioka T; Tanimoto A; Komiya S
BMC Musculoskelet Disord; 2011 Jul; 12():166. PubMed ID: 21774838
[TBL] [Abstract][Full Text] [Related]
34. Appropriate margin thresholds for isocontour metabolic volumetry of fluorine-18 fluorodeoxyglucose PET in sarcoma: a hybrid PET/MRI study.
Lee H; Paeng JC; Hong SH; Yoo HJ; Cheon GJ; Lee DS; Chung JK; Kang KW
Nucl Med Commun; 2016 Oct; 37(10):1088-94. PubMed ID: 27281357
[TBL] [Abstract][Full Text] [Related]
35. Intense accumulation of 18F-FDG, not enhancement on MRI, helps to guide the surgical biopsy accurately in soft tissue tumors.
Park JH; Park EK; Kang CH; Kim CH; Choe JG; Noh W
Ann Nucl Med; 2009 Dec; 23(10):887-9. PubMed ID: 19862481
[TBL] [Abstract][Full Text] [Related]
36. Contemporary imaging in sarcoma.
Landa J; Schwartz LH
Oncologist; 2009 Oct; 14(10):1021-38. PubMed ID: 19789392
[TBL] [Abstract][Full Text] [Related]
37. [Positron emission tomography as a tool for early prediction of therapy outcome in soft tissue sarcoma].
Kasper B; Schmitt T; Wuchter P; Ho AD; Egerer G
Dtsch Med Wochenschr; 2009 Sep; 134(39):1922-6. PubMed ID: 19760551
[TBL] [Abstract][Full Text] [Related]
38. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
[TBL] [Abstract][Full Text] [Related]
39. Carbon-11-thymidine and FDG to measure therapy response.
Shields AF; Mankoff DA; Link JM; Graham MM; Eary JF; Kozawa SM; Zheng M; Lewellen B; Lewellen TK; Grierson JR; Krohn KA
J Nucl Med; 1998 Oct; 39(10):1757-62. PubMed ID: 9776283
[TBL] [Abstract][Full Text] [Related]
40. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma.
Folpe AL; Lyles RH; Sprouse JT; Conrad EU; Eary JF
Clin Cancer Res; 2000 Apr; 6(4):1279-87. PubMed ID: 10778952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]